-
1
Fulminant myocarditis often requires temporary mechanical circulatory support (t-MCS) due to severely impaired left ventricular ejection fraction.
-
2
t-MCS technologies, such as VA-ECMO and IABP, provide hemodynamic stabilization but carry significant risks and require careful patient selection.
-
3
A recent study analyzed 295 patients treated with t-MCS, revealing a one-year mortality rate of 36% and a composite outcome of 44% for death, heart transplant, or LVAD.
-
4
The study highlights a diagnostic gap, as 31% of myocarditis cases were diagnosed clinically without definitive tools, emphasizing the need for reliable diagnostic methods.
-
5
Key uncertainties remain regarding the timing and efficacy of immunotherapy in t-MCS, as well as the optimal strategies for device use and patient selection.
